IDEXX Beats Q2 2026, Raises Guidance Again

A guidance raise is supposed to be the good news. Two quarters into 2026, IDEXX has delivered one twice in a row, and the growth rate underneath both raises has gotten smaller each time. IDEXX Laboratories reported Q2 revenue of $1.217 billion this week, up 10% as reported and 9% organically, and lifted its full-year outlook for the second consecutive quarter.

IDEXX posts 10% Q2 growth, raises guidance again

Q2 2026 revenue at IDEXX (NASDAQ: IDXX) came in at $1.217 billion, up 10% reported and 9% organic, against $1.1095 billion a year earlier. Diluted EPS was $4.27, up 18% reported and 15% on a comparable basis, versus $3.63 in the same quarter last year.

CAG Diagnostics recurring revenue, the company's largest and steadiest line, grew 11% reported and 10% organic. Water testing grew 15% reported and 13% organic. Livestock, Poultry and Dairy grew 11% reported and 9% organic. All three segments posted double-digit reported growth for the second straight quarter.

Management raised full-year 2026 guidance to revenue of $4.70 billion to $4.745 billion and EPS of $14.69 to $14.94, up from the $4.675 billion to $4.76 billion and $14.45 to $14.90 ranges set after Q1. Full-year organic growth guidance now sits at 8.5% to 9.7%, tightened from 7.7% to 9.7% previously. CEO Mike Erickson called it the kind of durable, compounding growth the company is building for the long term, framing it as helping veterinarians see more and do more for their patients.

Why the growth rate matters more than the beat

The number worth sitting with isn't the beat. It's the direction. IDEXX's first-quarter organic growth ran 11%. This quarter it's 9%. Two points of deceleration inside a guidance raise is an unusual combination, and it means the back half of the year is now carrying more of the weight for IDEXX to hit its own numbers.

That's not a crisis. CAG Diagnostics recurring revenue, the annuity-like line that comes from reagents and consumables running through instruments already on clinic benches, is still growing double digits. IDEXX has been widening that base methodically, most recently by adding taeniid tapeworm detection to its Fecal Dx reference-lab menu in May. Every menu addition gives a clinic one more reason to keep sending samples to IDEXX rather than running them on a bench microscope, and in a category where consumables already account for 88% of diagnostics revenue, menu depth is the moat, not instrument placement.

The installed base behind that recurring revenue has also been growing. In Q1, IDEXX placed 4,650 premium analyzers, including 1,100 InViewDX units, and grew Cancer Dx adoption to 7,500 practices. Every one of those placements is a multi-year reagent commitment, which is why a slowing top-line number doesn't necessarily mean a slowing annuity base underneath it.

Still, a slowing organic rate inside a raised guide tells operators something about where growth is coming from. Pricing, mix, and installed-base utilization can carry a quarter even as unit growth cools. That's a fine story for a diagnostics leader with real pricing power. It's a worse story if a competitor starts taking share on price or bundling, which is exactly the dynamic IDEXX was watching from Zoetis in Q1, when Zoetis printed flat organic growth and flagged an 11% drop in US companion animal sales. Whether that gap widened or narrowed in Zoetis's own Q2 print is one of the more useful comparisons operators can make once that number lands.

For veterinary-adjacent operators, the read is that diagnostics utilization per visit is still the number to track over visit volume, and it's still rising. But the run of double-digit organic growth compounding on double-digit organic growth may be starting to taper, which raises the stakes on adjacent categories like imaging, cloud software, and oncology screening to carry the next leg.

What Q3 guidance cadence will reveal next

IDEXX doesn't typically break out same-store clinical visit trends in its headline release, and this one didn't either, a contrast with the Q1 print that explicitly flagged a roughly 1% same-store visit decline. Whether that detail resurfaces on the earnings call, and whether visits stabilized or kept falling, will shape how much of Q2's growth came from utilization versus a friendlier comparison base.

Two things to watch heading into Q3: whether IDEXX raises guidance a third straight time, which would suggest the deceleration is measurement noise more than trend, and whether CAG Diagnostics organic growth reaccelerates toward 11% or keeps drifting toward high single digits. A third consecutive raise on a stabilizing growth rate would be the strongest signal yet that the diagnostics category has structurally decoupled from clinic traffic. A raise riding a further-decelerating rate would suggest IDEXX is leaning more on price and mix to hit numbers that used to come from volume.

Source: IDEXX Laboratories via Business Wire